DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qmmhc7/myelofibrosispipe) has announced the addition of the "Myelofibrosis-Pipeline Insights" report to their offering.
Myelofibrosis Pipeline Insights provides in-depth analysis of the pipeline assets across Myelofibrosis. The main objective of this report is to track competitor pipeline molecules, related research activities, technology, collaborations, and in-licensing and out-licensing deals. The Myelofibrosis Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
Myelofibrosis Pipeline Insights Report covers the Myelofibrosis pipeline molecules at various stages of development like pre-registration phase, clinical phases (Phase III, Phase II & Phase I), and pre-clinical and discovery phases. The Report also provides Myelofibrosis-related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in the pipeline for Myelofibrosis.
Scope
- The report provides a Myelofibrosis landscape across the globe
- The report provides drug profiles which include product description, MOA, licensors & collaborators, technology, development partner and chemical information
- Coverage of the Myelofibrosis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Myelofibrosis and also provides company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
For more information visit http://www.researchandmarkets.com/research/qmmhc7/myelofibrosispipe.
